BR112021022712A2 - Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida - Google Patents
Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamidaInfo
- Publication number
- BR112021022712A2 BR112021022712A2 BR112021022712A BR112021022712A BR112021022712A2 BR 112021022712 A2 BR112021022712 A2 BR 112021022712A2 BR 112021022712 A BR112021022712 A BR 112021022712A BR 112021022712 A BR112021022712 A BR 112021022712A BR 112021022712 A2 BR112021022712 A2 BR 112021022712A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- chlorodifluoromethoxy
- hydroxypyrrolidin
- pyrazol
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848857P | 2019-05-16 | 2019-05-16 | |
| US201962949599P | 2019-12-18 | 2019-12-18 | |
| PCT/IB2020/054628 WO2020230099A1 (en) | 2019-05-16 | 2020-05-15 | Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022712A2 true BR112021022712A2 (pt) | 2022-03-29 |
Family
ID=70775449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022712A BR112021022712A2 (pt) | 2019-05-16 | 2020-05-15 | Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11407735B2 (https=) |
| EP (1) | EP3969117B1 (https=) |
| JP (2) | JP2022532404A (https=) |
| KR (1) | KR102945602B1 (https=) |
| CN (1) | CN114144232A (https=) |
| AU (1) | AU2020276701B2 (https=) |
| BR (1) | BR112021022712A2 (https=) |
| CA (1) | CA3139812A1 (https=) |
| CL (1) | CL2021003011A1 (https=) |
| IL (1) | IL287995A (https=) |
| MX (1) | MX2021013970A (https=) |
| TW (2) | TWI853027B (https=) |
| WO (1) | WO2020230099A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI853027B (zh) | 2019-05-16 | 2024-08-21 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
| ES3057399T3 (en) | 2020-01-28 | 2026-03-02 | Tapi Czech Ind S R O | Solid state forms of asciminib and processes for the preparation thereof |
| WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
| CN114369085B (zh) * | 2021-12-27 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 盐酸Asciminib的制备方法 |
| WO2024100212A1 (en) | 2022-11-10 | 2024-05-16 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
| WO2024257116A1 (en) * | 2023-06-13 | 2024-12-19 | Natco Pharma Limited | Novel polymorphic forms of asciminib and its pharmaceutical salts thereof |
| WO2025032514A1 (en) * | 2023-08-07 | 2025-02-13 | Biophore India Pharmaceuticals Pvt. Ltd | A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| PT2861579T (pt) * | 2012-05-15 | 2018-04-27 | Novartis Ag | Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl |
| HUE031227T2 (en) | 2012-12-27 | 2017-07-28 | Zentiva Saglik Ueruenleri San Ve Tic A S | Dry granulation process for preparing metformin tablet compositions and compositions thereof |
| US10085993B2 (en) | 2014-07-25 | 2018-10-02 | Novartis Ag | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| EP3292870A1 (en) | 2016-09-08 | 2018-03-14 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Fibronectin for use in the treatment of leukemia |
| EP3519400A1 (en) | 2016-09-27 | 2019-08-07 | Novartis AG | Surfactant systems for crystallization of organic compounds |
| EP3700516B1 (en) | 2017-10-27 | 2024-01-24 | Sonic Master Limited | Inhibitors of dux4 induction for regulation of muscle function |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| TWI853027B (zh) | 2019-05-16 | 2024-08-21 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
-
2020
- 2020-05-14 TW TW109116067A patent/TWI853027B/zh active
- 2020-05-14 TW TW113128176A patent/TW202444706A/zh unknown
- 2020-05-14 US US16/874,622 patent/US11407735B2/en active Active
- 2020-05-15 BR BR112021022712A patent/BR112021022712A2/pt unknown
- 2020-05-15 MX MX2021013970A patent/MX2021013970A/es unknown
- 2020-05-15 CA CA3139812A patent/CA3139812A1/en active Pending
- 2020-05-15 AU AU2020276701A patent/AU2020276701B2/en active Active
- 2020-05-15 EP EP20726959.8A patent/EP3969117B1/en active Active
- 2020-05-15 KR KR1020217040723A patent/KR102945602B1/ko active Active
- 2020-05-15 WO PCT/IB2020/054628 patent/WO2020230099A1/en not_active Ceased
- 2020-05-15 CN CN202080051576.4A patent/CN114144232A/zh active Pending
- 2020-05-15 JP JP2021568319A patent/JP2022532404A/ja not_active Withdrawn
-
2021
- 2021-11-10 IL IL287995A patent/IL287995A/en unknown
- 2021-11-15 CL CL2021003011A patent/CL2021003011A1/es unknown
-
2022
- 2022-07-06 US US17/858,701 patent/US12252478B2/en active Active
- 2022-07-06 US US17/858,713 patent/US12252479B2/en active Active
-
2024
- 2024-03-21 JP JP2024045596A patent/JP2024095697A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12252478B2 (en) | 2025-03-18 |
| CA3139812A1 (en) | 2020-11-19 |
| IL287995A (en) | 2022-01-01 |
| EP3969117A1 (en) | 2022-03-23 |
| CL2021003011A1 (es) | 2022-09-09 |
| WO2020230099A1 (en) | 2020-11-19 |
| KR102945602B1 (ko) | 2026-03-31 |
| JP2022532404A (ja) | 2022-07-14 |
| KR20220009414A (ko) | 2022-01-24 |
| US20230089503A1 (en) | 2023-03-23 |
| US20230074064A1 (en) | 2023-03-09 |
| US11407735B2 (en) | 2022-08-09 |
| MX2021013970A (es) | 2022-01-04 |
| US12252479B2 (en) | 2025-03-18 |
| AU2020276701A8 (en) | 2022-05-12 |
| TWI853027B (zh) | 2024-08-21 |
| EP3969117B1 (en) | 2026-03-25 |
| AU2020276701A1 (en) | 2022-01-06 |
| US20200361904A1 (en) | 2020-11-19 |
| TW202110823A (zh) | 2021-03-16 |
| JP2024095697A (ja) | 2024-07-10 |
| AU2020276701B2 (en) | 2023-11-23 |
| TW202444706A (zh) | 2024-11-16 |
| CN114144232A (zh) | 2022-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022712A2 (pt) | Formas cristalinas de n-[4-(clorodifluorometóxi)fenil]-6-[(3r)-3-hidroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida | |
| CY1124414T1 (el) | Αναστολεις του υποδοχεα τελεστη αυξησης ινοβλαστων | |
| PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| MX2019013645A (es) | Inhibidores de quinasa y usos de los mismos. | |
| UA122528C2 (uk) | Сполуки, які модулюють fxr (nr1h4) | |
| EA201892480A1 (ru) | Соединения, модулирующие fxr (nr1h4) | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| JO3155B1 (ar) | معدِّل نكهة حلوة | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| EA201492056A1 (ru) | Пиримидиниловые ингибиторы тирозинкиназы | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| JOP20170100B1 (ar) | توليف مركبات إندازول | |
| EA201692003A1 (ru) | Макроциклические производные пиримидина | |
| EA201692000A1 (ru) | Макроциклические производные пиридина | |
| CR20180143A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca | |
| EA201790570A1 (ru) | Модуляторы р2х7 | |
| EA201692474A1 (ru) | Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2 | |
| PH12016501472B1 (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | |
| NZ742952A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| EA201501175A1 (ru) | Новые соединения для лечения злокачественного новообразования | |
| MX2016010272A (es) | Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |